SalaryGuide
AboutPricingFor Employers

Marketing jobs

4 marketing jobs

Acadia Pharmaceuticals Inc. logo
3 weeks ago

Director, Marketing - Rare Disease

Acadia Pharmaceuticals Inc.

San Diego, CA (Hybrid)Full time$199K/yr – $248K/yr
Acadia Pharmaceuticals logo
5 weeks ago

Executive Director, Consumer Marketing

Acadia Pharmaceuticals

South San Francisco, CA (Hybrid)Full time$271K/yr – $339K/yr
Acadia Pharmaceuticals Inc. logo
6 weeks ago

Senior Director, HCP Marketing

Acadia Pharmaceuticals Inc.

San Diego, CA (Hybrid)Full time$238K/yr – $298K/yr
Acadia Pharmaceuticals Inc. logo
4 months ago

Associate Director, HCP Marketing - Rare Franchise

Acadia Pharmaceuticals Inc.

Princeton, NJ (Hybrid)Full time$175K/yr – $219K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

4 jobs
Acadia Pharmaceuticals Inc. logo

Director, Marketing - Rare Disease

Acadia Pharmaceuticals Inc.

San Diego, CA (Hybrid)

$199K/yr - $248K/yrIn-houseFull-timeDirector/executive10+ years exp.
3 weeks ago
Acadia Pharmaceuticals logo

Executive Director, Consumer Marketing

Acadia Pharmaceuticals

South San Francisco, CA (Hybrid)

$271K/yr - $339K/yrIn-houseFull-timeDirector/executive15+ years exp.
5 weeks ago
Acadia Pharmaceuticals Inc. logo

Senior Director, HCP Marketing

Acadia Pharmaceuticals Inc.

San Diego, CA (Hybrid)

$238K/yr - $298K/yrIn-houseFull-timeSenior level12+ years exp.
6 weeks ago
Acadia Pharmaceuticals Inc. logo

Associate Director, HCP Marketing - Rare Franchise

Acadia Pharmaceuticals Inc.

Princeton, NJ (Hybrid)

$175K/yr - $219K/yrIn-houseFull-timeSenior level8+ years exp.
4 months ago
Acadia Pharmaceuticals Inc. logo
Acadia Pharmaceuticals Inc.

Director, Marketing - Rare Disease

San Diego, CA (Hybrid)

$199K/yr – $248K/yrDirector/Executive10+ years expFull time

Posted 3 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own Rett-focused consumer and caregiver marketing, shaping messaging, DTC TV, and speaker programs while aligning with field education and MLR guidance.

  • Clarify ownership of brand strategy, messaging, and ROI-driven programs for caregivers and families.
  • Lead the caregiver speaker program end to end, from selection and content to effectiveness analysis.
  • Coordinate cross-functional marketing with FSE and medical/legal review to deliver a compliant, patient- and caregiver-centric experience.

Job Description

Responsibilities

  • Lead the development and execution of consumer and caregiver marketing initiatives, including core messaging, direct-to-consumer (DTC) television advertising, and educational materials designed to inform, support, and empower families within the Rett community.
  • Oversee the caregiver speaker program, including speaker identification, onboarding, and management; development of compliant, engaging speaker content; and ongoing evaluation and optimization of program effectiveness.
  • Ensure caregiver speaker materials and presentations are scientifically accurate, compliant, and aligned with brand strategy, with a strong emphasis on clarity, empathy, and patient- and caregiver-focused storytelling.
  • Serve as the primary marketing liaison to the Family Support Educator (FSE) team, ensuring alignment between consumer marketing initiatives and field-based educational efforts to deliver a cohesive and consistent caregiver experience.
  • Directs the development of strategic marketing programs for inclusion into brand plan, determines metrics for program success, and evaluates performance against metrics including contributions to the development and evolution of message strategy based upon in-depth analytics and ROI analysis.
  • Manages within the established the US promotions budget for assigned products.
  • Represents the department as a member of cross-functional project teams providing guidance, insight, and recommendations relative to the goals and objectives of the Marketing function to ensure strategic alignment medical education messaging across groups.
  • Monitors and ensures that all Medical Legal Review (MLR) processes are followed, and all programs are compliant with legal guidance and corporate policies.
  • Implements the brand strategy for products and product lines. Develops and delivers presentations as needed to commercial management and other internal groups. Monitors progress of plans and recommends adjustments, as necessary.
  • Develops and maintains strong external relationships with Advocacy groups, physician speakers and Rett caregivers and families.

Requirements

  • Bachelor’s degree in marketing, health care, life science; master’s degree preferred.
  • Targeting 10+ years of progressively responsible experience in pharmaceutical or biotech Marketing.
  • 5+ years in a product manager role strongly desired.
  • Rare Disease experience is highly desirable, with requirement of understanding specialty therapeutics addressing significant unmet medical needs.
  • Strong Biopharmaceutical brand management experience and demonstrated track record of success.
  • Proficient in marketing and media tactics directed towards HCPs and caregivers.
  • Proficient at effectively prioritizing goals and coordinating resources to achieve those goals.
  • Demonstrated ability to interface/collaborate with other departments as necessary to achieve goals.
  • Significant travel required; ability to travel up to 50% of time during peak launch time periods.

Preferred

  • 5+ years in a product manager role strongly desired.
  • Launch experience and commercialization of new products preferred.
  • Master’s degree preferred.

Benefits

  • What we offer US-based Employees: - Competitive base, bonus, new hire and ongoing equity packages
  • Medical, dental, and vision insurance
  • Employer-paid life, disability, business travel and EAP coverage
  • 401(k) Plan with a fully vested company match 1:1 up to 5%
  • Employee Stock Purchase Plan with a 2-year purchase price lock-in
  • 15+ vacation days
  • 13 -15 paid holidays, including office closure between December 24th and January 1st
  • 10 days of paid sick time
  • Paid parental leave benefit
  • Tuition assistance
Acadia Pharmaceuticals Inc. logo

Acadia Pharmaceuticals Inc.

3.1 Glassdoor

At Acadia, our mission is to turn scientific promise into meaningful innovation that makes the difference for underserved neurological disorders and rare disease communities around the world. Our commercial portfolio includes FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with early-stage programs that address other unmet patient needs.

Founded in 1993
San Diego, California, USA
921 employees (54 in marketing)
Acadia.com
43% recommend to a friend
49% CEO approval

Traffic Signals

Monthly Visitors
35.6K
Traffic Source Mix
Search
36.9%
Direct
49.4%
Referral
5.5%
Social
7.3%
Paid
0.7%

Headcount Trend

Current headcount: ~921

Marketing Team

Marketing Team Size
52 (6% of company)
Median Career Experience
20 years
Median Tenure
3.5 years
Marketing Roles Posted (Last 30 Days)
2

People

Marketing Leadership

Aine Scibelli
Aine Scibelli
Sr. Director Consumer Marketing
At the company for 1 year
Kristin S.
Kristin S.
Director, Marketing Rare Disease
At the company for 3 years 6 months
Clement H.
Clement H.
Associate Director, Regional Marketing Liaison
At the company for 1 year 2 months
Marc Haskins, MBA
Marc Haskins, MBA
Associate Director, Regional Marketing Liaison, Rare Disease
At the company for 1 year 3 months

Funding

Total Funding
$811.7M
Last Raise
$287.5M
Post IPO Equity, 6 years ago

Funding History

  • Sep 2019
    Post IPO Equity • $287.5M
  • Nov 2018
    Post IPO Equity • $316.2M
  • Jan 2013
    Post IPO Equity • $86.4M

Recent News

ACADIA Pharmaceuticals Q3 2025 Earnings Call Highlights
Nov 15, 2025 • MSN
How ACADIA Pharmaceuticals Inc. stock performs after earnings - July 2025 Weekly Recap & Real-Time Chart Pattern Alerts
Nov 14, 2025 • newser.com
Shareholders Shouldn’t Be Too Comfortable With ACADIA Pharmaceuticals' (NASDAQ:ACAD) Strong Earnings
Nov 13, 2025 • simplywall.st
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position
Nov 13, 2025 • Yahoo Finance
Director Cashes Out: Major Stock Sale at ACADIA Pharmaceuticals!
Nov 13, 2025 • TipRanks
Acadia Pharmaceuticals director Daly sells $670k in stock
Nov 12, 2025 • investing.com
Should Raised Revenue Guidance After Strong Q3 Earnings Require Action From ACADIA Pharmaceuticals (ACAD) Investors?
Nov 7, 2025 • Sahm
Beyond The Numbers: 6 Analysts Discuss ACADIA Pharmaceuticals Stock
Nov 6, 2025 • Benzinga
Acadia Pharmaceuticals stock price target lowered to $32 at RBC Capital
Nov 6, 2025 • investing.com
ACADIA Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Nov 6, 2025 • TradingView
ACADIA Pharmaceuticals Q3 2025 Earnings: EPS Soars to $0.42, Rev
Nov 5, 2025 • GuruFocus
Earnings call transcript: ACADIA Pharmaceuticals beats Q3 2025 EPS forecast
Nov 5, 2025 • investing.com
Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates
Nov 5, 2025 • Yahoo Finance
ACADIA Pharmaceuticals Surges 53% as New Product Launches Fuel Fresh Valuation Debate
Nov 1, 2025 • simplywall.st
ACADIA Pharmaceuticals Advances Alzheimer’s Disease Psychosis Study with ACP-204
Oct 29, 2025 • TipRanks
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Oct 28, 2025 • Yahoo Finance
How ACADIA Pharmaceuticals Inc. stock performs after earnings - Weekly Trade Analysis & Capital Efficiency Focused Ideas
Oct 24, 2025 • newser.com
How ACADIA Pharmaceuticals Inc. stock performs after earnings - 2025 Sector Review & Daily Chart Pattern Signal Reports
Oct 23, 2025 • newser.com
Is ACADIA Pharmaceuticals Inc. stock trading near support levels - July 2025 Price Swings & High Return Trade Guides
Oct 23, 2025 • newser.com
Is ACADIA Pharmaceuticals Inc. reversing from oversold territory - Fed Meeting & Real-Time Buy Signal Alerts
Oct 23, 2025 • newser.com
ACADIA Pharmaceuticals Inc. stock trend outlook and recovery path - Forecast Cut & Expert Curated Trade Ideas
Oct 22, 2025 • newser.com
This ACADIA Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Oct 21, 2025 • Benzinga
News impact scoring models applied to ACADIA Pharmaceuticals Inc. - Trade Exit Summary & Technical Pattern Based Buy Signals
Oct 21, 2025 • newser.com
Is ACADIA Pharmaceuticals Inc. reversing from oversold territory - Earnings Recap Report & Weekly Watchlist for Consistent Profits
Oct 21, 2025 • newser.com
Acadia Pharmaceuticals’ CEO on rebranding, using AI as a small biotech
Oct 20, 2025 • Medical Marketing and Media
Real time alert setup for ACADIA Pharmaceuticals Inc. performance - July 2025 Trends & Short-Term Swing Trade Alerts
Oct 20, 2025 • newser.com
What dividend safety score for ACADIA Pharmaceuticals Inc. stock - 2025 Valuation Update & Real-Time Market Trend Scan
Oct 18, 2025 • Trung tâm Dự báo KTTV quốc gia
Hedge Fund Moves: Is ACADIA Pharmaceuticals Inc. stock attractive after correction - July 2025 Movers & Fast Gaining Stock Strategy Reports
Oct 18, 2025 • nchmf.gov.vn
ACADIA Pharmaceuticals Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Oct 15, 2025 • Investor's Business Daily
Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025
Oct 15, 2025 • Business Wire
ACADIA Pharmaceuticals: Nuplazid And Daybue Are Enough To Remain Bullish (ACAD)
Oct 6, 2025 • Seeking Alpha
ACADIA Pharmaceuticals Inc. Securities Lawsuit Investigation
Oct 3, 2025 • Claim Depot
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Oct 3, 2025 • PR Newswire
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson’s Disease and Movement Disorders®
Oct 2, 2025 • Yahoo Finance
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure
Sep 25, 2025 • Zacks Investment Research
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Sep 25, 2025 • BioSpace
Acadia Pharmaceuticals: Reeling After PWS Failure - Downgrading To Hold (NASDAQ:ACAD)
Sep 24, 2025 • Seeking Alpha
Acadia Scraps Prader-Willi Drug After Late-Stage Failure
Sep 24, 2025 • BioSpace
Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno
Sep 24, 2025 • Fierce Pharma
Acadia to scrap Prader-Willi drug after study setback
Sep 24, 2025 • Yahoo Finance
Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study
Sep 24, 2025 • statnews.com
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Sep 24, 2025 • Business Wire
Acadia pulls plug on Prader-Willi drug after trial flop
Sep 24, 2025 • FirstWord Pharma
Oversold Conditions For Acadia Pharmaceuticals (ACAD)
Sep 24, 2025 • Nasdaq
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Sep 24, 2025 • MarketScreener
ACADIA Pharmaceuticals (ACAD) Announces Interim Results From LOTUS study on DAYBUE
Sep 23, 2025 • Yahoo Finance
Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study
Sep 23, 2025 • Stocktwits
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid CNS market challenges
Sep 22, 2025 • Investing.com
Acadia Pharma EVP Schneyer sells $82,727 in stock
Sep 16, 2025 • investing.com
ACADIA Pharmaceuticals (ACAD) Reports Positive Interim Results From Rett Syndrome Study
Sep 13, 2025 • Yahoo Finance
90% Patient Improvement: Groundbreaking DAYBUE Drug Shows Long-term Success in Rare Rett Syndrome Study
Sep 12, 2025 • Stock Titan
Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology
Sep 12, 2025 • Morningstar.com
Sanofi, Gilead, Acadia win big at the 2025 Fierce Pharma Marketing Awards
Sep 11, 2025 • Fierce Pharma
161,676 Stock Options at $25.50: Acadia Pharmaceuticals Issues Major Inducement Grants to New Hires
Sep 8, 2025 • Stock Titan
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
Sep 3, 2025 • CDO Magazine
ACADIA Pharmaceuticals Inc. (ACAD) Nears Phase 3 Readout in Prader-Willi Syndrome Trial
Aug 29, 2025 • Yahoo Finance
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 26, 2025 • BioSpace
Acadia Names Konstantina Katcheves as Senior VP, Chief Business & Strategy Officer
Aug 26, 2025 • contractpharma.com
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Aug 26, 2025 • Stock Titan
Acadia Pharmaceuticals to Participate at Upcoming September 2025 Investor Conferences
Aug 26, 2025 • BioSpace
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Aug 26, 2025 • Business Wire
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • Yahoo Finance
Acadia Pharmaceuticals appoints Katcheves as chief business officer
Aug 25, 2025 • investing.com
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • MarketScreener
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • Business Wire
Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer
Aug 25, 2025 • PharmiWeb
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story
Aug 14, 2025 • Yahoo Finance
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 9, 2025 • Yahoo Finance
ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations
Aug 8, 2025 • Yahoo Finance
ACADIA Pharmaceuticals Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:ACAD) 2025-08-07
Aug 7, 2025 • Seeking Alpha
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts
Aug 7, 2025 • Investing.com
Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview
Aug 7, 2025 • BioSpace
Acadia Pharmaceuticals Q2 2025 slides: revenue up 9%, raises full-year guidance
Aug 6, 2025 • investing.com
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
Aug 6, 2025 • Yahoo Finance
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
Aug 5, 2025 • citybiz
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer
Aug 4, 2025 • Yahoo Finance
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Jul 30, 2025 • Yahoo Finance
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
Jul 24, 2025 • BioSpace
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025
Jul 23, 2025 • Business Wire
Acadia Debuts New Team, Pipeline With ‘Biotech Powerhouse’ Ambitions
Jul 15, 2025 • BioSpace
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Jul 10, 2025 • Investor's Business Daily
Asperger Syndrome Market 2025: Strategic Insights for Business Growth, Expansion, and Competitive Edge
Jul 4, 2025 • EIN Presswire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 3, 2025 • MarketScreener
Acadia CEO sets sights on ‘much more assertive’ deals to invigorate pipeline
Jul 2, 2025 • BioPharma Dive
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 2, 2025 • Business Wire
currIQūnet Rebrands as Acadea, Ushering in a Smarter Era for Curriculum Management in Higher Education
Jul 2, 2025 • EIN Presswire
Acadia’s ‘very bullish’ sales forecast restores some confidence on Wall Street
Jun 26, 2025 • BioPharma Dive
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Jun 25, 2025 • Yahoo Finance
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Jun 25, 2025 • BioSpace
Acadia plans seven late-stage trials, five readouts through 2027
Jun 25, 2025 • Investing.com
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Jun 25, 2025 • sdbn.org
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers
Jun 25, 2025 • Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 17, 2025
Jun 18, 2025 • BioSpace
Acadia Pharmaceuticals reports inducement grants under Nasdaq listing rule
Jun 17, 2025 • Reuters
US Appeals Court Confirms Patent Validity of Acadia’s Parkinson’s Medication
Jun 11, 2025 • Yahoo Finance
Fed Circ affirms rulings in Acadia’s fight against Parkinson’s drug copies
Jun 10, 2025 • Life Sciences Intellectual Property Review
US appeals court upholds Acadia’s patent for Parkinson’s drug in MSN Labs case
Jun 10, 2025 • Hindu Business Line
US appeals court confirms patent validity of Acadia's Parkinson's drug
Jun 9, 2025 • Reuters
Acadia Win On Parkinson's Drug Patent Upheld By Fed. Circ.
Jun 9, 2025 • Law360
U.S. Court Of Appeals For The Federal Circuit Affirms Prior Delaware District Court Rulings In Favor Of Acadia In Nuplazid® (Pimavanserin) Composition Of Matter Patent
Jun 9, 2025 • MarketScreener